Gitlin M J, Weiner H, Fairbanks L, Hershman J M, Friedfeld N
Department of Psychiatry, University of California, Los Angeles 90024.
J Affect Disord. 1987 Nov-Dec;13(3):267-72. doi: 10.1016/0165-0327(87)90046-2.
Despite a lack of documented efficacy in controlled trials, triiodothyronine (T3) is frequently administered as an adjunctive therapy for tricyclic resistant depressions. In this study, we tested the efficacy of T3 as an adjunctive treatment using a double-blind, placebo-controlled crossover design. Sixteen depressed patients who were unresponsive to 4 weeks of imipramine therapy (mean dose = 206 +/- 54 mg daily, mean combined blood level = 220 +/- 132 ng/dl) received T3 25 micrograms and placebo for 2 weeks each. There was no evidence of a T3 effect using both Hamilton depression scores and global improvement. No subgroup of responders using baseline TRH stimulation tests could be identified. T3 treatment lowered plasma free T4 (P = 0.001) and TSH (P greater than 0.02) while raising plasma T3 levels (P less than 0.01), indicating the physiological effect of the drug.
尽管在对照试验中缺乏疗效记录，但三碘甲状腺原氨酸（T3）仍经常作为三环类耐药抑郁症的辅助治疗药物使用。在本研究中，我们采用双盲、安慰剂对照交叉设计测试了T3作为辅助治疗的疗效。16名对4周丙咪嗪治疗无反应的抑郁症患者（平均剂量=每日206±54毫克，平均联合血药浓度=220±132纳克/分升）分别接受25微克T3和安慰剂治疗，各为期2周。使用汉密尔顿抑郁评分和整体改善情况均未发现T3有疗效证据。无法根据基线促甲状腺激素释放激素刺激试验确定有反应的亚组。T3治疗降低了血浆游离T4（P=0.001）和促甲状腺激素（P>0.02），同时提高了血浆T3水平（P<0.01），表明该药物具有生理效应。
